Roche Buys IL-2 Technology From Good, Which Forms New Firm Bonum
Roche is paying $250m up front to buy Good Therapeutics, which will launch a new company, Bonum Therapeutics, to explore its platform technology for targets other than interleukin-2.
You may also be interested in...
GSK takes equity stake in Spero, and global rights to tebipenem except for certain Asian markets. Merck KGaA gets rights to Nerviano’s next-generation PARP inhibitor for cancer.
Nektar/BMS Deal Takes Second Gut Punch As IL-2/PD-1 Combo Goes Down In Flames
Nektar Therapeutics, Alkermes and Roche are among the companies with new solutions for more safely targeting an old cytokine well validated in cancer immunotherapy. Top execs explain how and why.